0.35Open0.35Pre Close0 Volume102 Open Interest2.50Strike Price0.00Turnover0.00%IV-5.32%PremiumDec 20, 2024Expiry Date0.51Intrinsic Value100Multiplier19DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma8.60Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Protara Therapeutics Stock Discussion
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
Protara Therapeutics (Nasdaq: TARA) announced upcoming presentation of interim data from its Phase 2 ADVANCED-2 trial of TARA-002 for non-muscle invasive bladder cancer (NMIBC) at the Society of Urologic Oncology Annual Meeting. The presentation will include safety data and new efficacy...
Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
• 78% of patients dependent on parenteral support were choline deficient, with 63% of these patients demonstrating liver dysfunction, including steatosis, cholestasis, and hepatobiliary injury
• IV Choline Chloride could fill a significant unmet medical need for th...
soon?
In a significant development for the biopharmaceutical industry, Protara Therapeutics, a company dedicated to identifying and advancing transformative therapies for rare and specialty diseases, announced an oversubscribed $45 million private placement financing. This milestone is no...
Chart watchers know that means bulls are losing their control, and the trend may reverse.
Meanwhile, technical indicators are suggesting movement biased to the Neutral < Buy territory.
Here's a little tidbit about TARA:
TARA IS A LONG HOLD. FORECASTING Q2 CATALYSTS WILL SEND THIS INTO DOUBLE DIGITS! BUY LOW, SELL HIGH!
No comment yet